NEW YORK (GenomeWeb News) – Cepheid said this week that it released an improved Xpert BCR-ABL Monitor test as a CE IVD product in the European Union. The firm said that the new test, which is used to monitor patients with chronic myelogenous leukemia, detects BCR-ABL chromosomal translocation in about 2 hours as compared to 2.5 hours for the original product release.
Enigma Diagnostics disclosed this week that the European Patent Office recently rejected a claim from Becton Dickinson in opposition to a patent filed by the firm. The Porton Down, England-based molecular diagnostics startup also said that the European Patent Office issued it a patent for the use of endonuclease-based reporting in PCR and other nucleic acid amplification technologies, which was at the center of the dispute with BD.
Enigma is developing a fully automated molecular diagnostics system for point-of-care testing.